Send E-mail
  • DSK subsidiary takes over Medica Korea for US$32.9m　
    DSK subsidiary takes over Medica Korea for US$32.9m　
    DSK (109740) said its subsidiary Protox will take over Medica Korea by acquiring 51 percent of its stake and the management rights for 38 billion won (US$32.9 million), in a statement on July 7.　To finance this acquisition, DSK will issue 20 billion won (US$17.3 million) worth bonds with warrants for Taurus Investment & Securities, it said in a separate announcement. 　Protox is developing protoxin, nondiffusible b...
From
Send to
Close Send

DSK subsidiary takes over Medica Korea for US$32.9m　

July 8, 2016 - 11:37 By 황유미
[DISCLOSURE] DSK (109740) said its subsidiary Protox will take over Medica Korea by acquiring 51 percent of its stake and the management rights for 38 billion won (US$32.9 million), in a statement on July 7.

To finance this acquisition, DSK will issue 20 billion won (US$17.3 million) worth bonds with warrants for Taurus Investment & Securities, it said in a separate announcement.

Protox is developing protoxin, nondiffusible botulinum toxin, and by merging with the privately held pharmaceutical company, will secure a manufacturing facility for the product.
Most Popular